Obstructive sleep apnoea (OSA) is a common disorder that can present with various clinical Background -Although oral appliances are effective in some patients with ob-consequences.
nCPAP nCPAP therapy was undertaken with either a REMstar Choice machine (Respironics Inc, Murrysville, Pennsylvania, USA) or a Tranquillity Plus machine (Healthdyne Technologies, Marietta, Georgia, USA) which were the most advanced nCPAP units available at the time of the study. Patients used various different airway access devices based on their own preference. The use of a cold flow-by humidifier was optional although encouraged. Intranasal corticosteroids and/or anticholinergic medications were used to relieve any nasal symptoms caused by the nCPAP. All patients underwent overnight polysomnography at the beginning of the nCPAP treatment period to determine the optimal pressure necessary to completely relieve the OSA.
   
All patients underwent a complete history and physical examination before recruitment to the questions about symptoms, treatment efficacy, side effects, and patient satisfaction was administered during the wash-in and wash-out period and at the end of each treatment period. The Epworth sleepiness scale questionnaire 9 was also administered at these times. Side cruited for this prospective crossover study. effects were rated both in terms of frequency Patients were unselected apart from a re-(never, rarely, sometimes, often) and severity quirement that they had at least 10 teeth in (absent, mild, moderate, severe). Patient sateach of the maxillary and mandibular arches, isfaction was rated either very satisfied, modand lived in the metropolitan Vancouver area. erately satisfied, moderately dissatisfied, or very All patients were seen in the Sleep Disorders dissatisfied. At the end of the study each patient Clinic at the Vancouver Hospital and Health was asked whether they would prefer to use Sciences Centre between February 1993 and AMP or nCPAP as a long term treatment. April 1994. The patients did not have to pay for either treatment. Each patient gave informed written consent and the study protocol was   approved by the clinical screening committee Each patient underwent overnight polyfor research and other studies involving human somnography before recruitment to the study. subjects at the University of British Columbia. Sleep and its stages were documented by standard electroencephalographic (EEG), electrooculographic (EOG), and electromyographic (EMG) criteria. 12 The EEG was recorded with  Oral appliance electrodes applied at C3-A2 and C4-A1 (according to the International 10-20 system) and The anterior mandibular positioner (AMP) used during this study is a new appliance with EMG activity was recorded from the submental muscles. Oronasal airflow was recorded by an several novel features (fig 1) . It is constructed of a methyl methacrylate material (SR-Ivocap; infrared CO 2 analyser (Model 1260; Novamatrix Medical Systems Inc, Wallingford, Elastomer Ivoclar Co, New York, USA) and the upper and lower portions of the appliance Connecticut, USA). A single ECG lead (modified V 2 ) was monitored to detect cardiac provide full occlusive coverage of the teeth. A titanium hinge with five holes connects the arrhythmias. Oxygen saturation (Sa 2 ) was monitored continuously with a pulse oximeter upper and lower portions. This hinge allows a small amount of lateral movement of the jaw. (Model N-100; Nellcor Inc, Hayward, California, USA) attached to the index finger. Chest There is a space between the teeth to permit oral airflow. The amount of the mandibular wall movement was monitored by a respiratory inductive plethysmograph (Respitrace; Amadvancement was initially set at 70% of maximal mandibular advancement. The AMP was bulatory Monitoring Equipment, Ardsley, New York, USA). The data were recorded on a 15-adjusted to maximise comfort by relieving pressure points on the teeth and gums. The amount channel polygraph (Model 78; Grass Instruments Co, Quincy, Massachusetts, USA) of mandibular advancement was then progressively increased over the next three months into the CNS Sleep Lab System (Model 200; CNS, Inc., Chanhassen, Minnesota, USA). All by a mean (SD) of 1.8 (1.2) mm until snoring ceased and symptoms improved (11 patients), of these studies were manually scored for sleep stage, apnoea type, and duration. Obstructive or until the patient could not tolerate further advancement (nine patients).
apnoeas were defined as the cessation of airflow group.bmj.com on April 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from for at least 10 seconds accompanied by ongoing comply with nCPAP the use of a humidifier was encouraged and the type of airway access respiratory effort, central apnoeas were defined as the cessation of airflow and respiratory effort device was often changed. Treatment success was defined as a resolution of symptoms and for at least 10 seconds, mixed apnoeas were defined as a combination of an obstructive and a reduction in AHI to <10/hour and treatment failure was defined as ongoing clinical sympcentral apnoea lasting for at least 10 seconds, and hypopnoeas were defined as a decrease of toms and/or a reduction in AHI to >10/hour.
Compliance failure was defined as an inability more than 50% in thoracoabdominal amplitude (Respitrace sum) for at least 10 seconds. The or unwillingness of the patient to use the treatment. severity of OSA was assessed in terms of the AHI.
 
The data were analysed according to the    Home sleep monitoring was performed with the method of Jones and Kenward. 13 Each patient received the treatments in one of two possible Poly-G Portable Apnoea Recorder and Sleep I/T-8 (CNS Inc, Chanhassen, Minnesota, orders: sequence A (AMP followed by nCPAP) or sequence B (nCPAP followed by AMP). USA).
10 This combined system recorded EEG (C3-A1), limb EMG, EOG, ECG, oronasal The treatment effect was estimated using the differences of the pairs of observations from airflow (thermistor), respiratory effort (chest and abdomen), arterial oxygen saturation each patient (before and after treatment). In order to rule out a treatment-by-period inter-(Sa 2 ), body position, and limb activity. The data were stored and the real time respiratory action, a test for carryover effect and period effect was performed.
14 The questionnaire and data were later regenerated for analysis. This allowed full manual analysis of the respiratory the home sleep monitoring data were analysed by groups such that the results of nCPAP in data (airflow, respiratory effort, and oxygen saturation). Sleep staging was done by a re-sequence A were compared with the results of nCPAP in sequence B. This was also performed cently validated automated analysis 11 as the raw EEG, EOG, and EMG data are not available for the AMP treatment from sequences A and B. Comparisons were also made between the with this monitoring system. different treatments in each sequence (AMP versus nCPAP for sequences A and B). The results were pooled if there was no difference   Upright lateral cephalometry was performed in between the same treatment from the different sequences and if the differences between the all patients before AMP treatment and at the same time as the AMP in one patient who had two treatments within each sequence were the same for sequences A and B. The data obtained an increase in AHI with AMP treatment. The analysis of the craniofacial, hyoid position, during the wash-in and wash-out periods before AMP and before nCPAP were compared to upper airway size, and soft tissue data has recently been described in detail. 12 ensure that the baseline values preceding each treatment were the same. The questionnaire symptom data were grouped into three possible responses -improved, unchanged, or worse.
 
The study consisted of a two week wash-in The home sleep monitoring data were then compared in the same manner as described period following the initial diagnostic polysomnogram. During this time the patients were above before pooling. The symptom, side effect, and compliance data were compared by not treated and baseline home sleep monitoring was performed. The questionnaires were ad-the Prescott test. The data from AMP sequence A were compared with AMP sequence B, and ministered during the wash-in period. The patients were also weighed at this time and, those from nCPAP sequence A were compared with nCPAP sequence B by an unpaired t subsequently, on each occasion the questionnaires were administered. The patients test. The results from AMP sequence A were compared with nCPAP sequence A and those were then randomised to treatment with either AMP or nCPAP. The questionnaires and home from AMP sequence B were compared with nCPAP sequence B by a paired t test. The final sleep monitoring were repeated at the end of the four month treatment period. The patient comparisons were made between treatments with a paired t test on the pooled AMP and then had a two week wash-out period during which they were not treated. At the end of nCPAP treatment effect from both treatment sequences. Data that were not normally disthis wash-out period the questionnaires were administered and home sleep monitoring was tributed were log transformed prior to comparison. Single logistic regression analysis was performed. The patient then underwent a second four month treatment period with the other performed to determine whether any clinical, polysomnographic, and cephalometric varitreatment. The questionnaires were administered and home sleep monitoring was ables were associated with a successful treatment outcome. performed at the end of this treatment period. Patients were seen monthly during each treatment period. When patients had side effects or were unable to comply with AMP treatment it Results
Twenty four patients (19 men) with sympwas re-adjusted to maximise comfort. When patients had side effects or were unable to tomatic OSA were recruited to the study. They group.bmj.com on April 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from fig 2) . This represents a reduction of apfailure). All subsequent results are presented proximately 44% in the AHI with AMP. There on the remaining 20 patients. There was no were eight treatment failures in whom the AHI carry-over effect between the treatment periods was not reduced to <10/hour (seven patients) or and no period effect on the home sleep moniin whom there were ongoing clinical symptoms toring data so these data from the AMP and (one patient). Two of the treatment failures nCPAP were pooled between the two different had an increase in AHI with AMP (from 30.7/ treatment sequences. There were no significant hour to 40.6/hour (32%) and from 24.3/hour differences in the home sleep monitoring data to 48.6/hour (100%)). The maximum intrameasured before treatment with the AMP and subject variability in AHI between the washthose measured before treatment with nCPAP.
in and wash-out periods was 38.5/hour to 55.5/ There was no significant change in body weight hour (44%). during either the AMP or nCPAP treatment Twenty patients used nCPAP and 19 had periods.
follow up home sleep monitoring because one Twenty patients were treated with the AMP of the compliance failures with nCPAP stopped and one (5%) was considered to be a comtreatment before a follow up home sleep monipliance failure. The remaining 19 patients had toring could be performed. The pre-treatment follow up home sleep monitoring performed AHI from home sleep monitoring was 23.5 with the AMP. There was no difference in (16.1)/hour and decreased with nCPAP to 4.2 the time spent sleeping in the supine position (2.2)/hour (p <0.005; table 2, fig 3) . The AHI during the pre-treatment period or during was lower with nCPAP than with AMP (mean home sleep monitoring with the AMP. The difference 10.2 (14.7)/hour; p <0.01, 95% con-AHI measured at home before treatment was fidence interval 2.9 to 17.5). The number of desaturations was less with nCPAP than with AMP (mean difference 11.1 (18.5)/hour; p <0.05, 95% confidence intervals 3.6 to 18.6) There was no change in sleep architecture or 
mean (SE).
group.bmj.com on April 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from These included sore teeth, sore jaw muscles, effects from nCPAP included nasal congestion, rhinorrhea, eye irritation, and a sense of suffocation. At the end of the four months four sleep efficiency with either AMP or nCPAP (table 2) .
patients (20%) treated with nCPAP had mild side effects, three (15%) had moderate side Both the AMP and nCPAP were effective in reducing symptoms associated with OSA (table effects, and three (15%) had severe side effects.
Three patients discontinued nCPAP treatment 3). Snoring was still present in 45% of patients with the AMP but was absent in all patients early either because of side effects, machine noise, or the inconvenience of using nCPAP. with nCPAP. Excessive daytime sleepiness, as measured by both symptoms and the Epworth The patient who did not have follow up home sleep monitoring with nCPAP discontinued sleepiness scale, was improved with both treatments. The Epworth sleepiness scale decreased using it because of severe nasal symptoms.
There was no significant difference in side with AMP from 10.3 (3.1) to 4.7 (2.6) (p <0.005) and with nCPAP from 11.0 (3.8) to effects between the treatments but the patients were less satisfied with nCPAP (p <0.01). Six-5.1 (3.3) (p <0.05), but the decrease was not different between the two treatments.
teen patients (80%) were moderately or very satisfied with the AMP and 14 patients (70%) Mild side effects were common with AMP, particularly in the first month of treatment. were very or moderately satisfied with nCPAP. group.bmj.com on April 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from Discussion This study is one of the first prospective clinical studies to compare an oral appliance with nCPAP in the treatment of an unselected group of patients with mild to moderate OSA. AMP was found to be an effective treatment in some of these patients with a success rate of 55% in the AMP group and 70% in the nCPAP group. However, nCPAP was more effective at improving both AHI and sleep arterial oxygen desaturation. Both treatments improved symptoms and subjective daytime sleepiness. There was no difference in reported compliance or side effects between the treatments but the AMP was associated with greater patient satisfaction than nCPAP. The long term preference was overwhelmingly in favour of AMP therapy with 10 of the 11 patients who were successfully treated with the AMP preferring it as their long term treatment option. Only six patients in the study preferred nCPAP as their long term treatment option.
Our study provides no insights into which patients are most likely to achieve a successful treatment outcome with an oral appliance. Previous studies have suggested that the tongue retaining device is more successful in non- posed that patients with milder OSA are more likely to benefit from mandibular repositioning appliances. 6 Eveloff and colleagues performed lateral cephalometry in patients with OSA with and without a mandibular repositioning apAt the end of the study 10 of the 11 patients who were treatment successes with AMP preferred it pliance and compared the responders and nonresponders. 8 They found that a shorter soft to nCPAP and one preferred nCPAP to AMP as a long term treatment. Five of the remaining palate and a decreased distance between the hyoid bone and the mandibular plane were patients preferred nCPAP, one patient used a different oral appliance, one patient proceeded both associated with a successful treatment
outcome. An important finding in our study is with uvulopalatopharyngoplasty, and two elected to continue with AMP therapy despite an that two patients developed more severe OSA with AMP treatment. We do not believe that AHI of >10/hour because their symptoms were relieved and they were unable to tolerate this increase in the severity of OSA with AMP is explained by intrasubject variability as in at nCPAP. Eight patients were treatment successes with both treatments, seven of whom least one of these two patients the increase in AHI was much greater than the maximum preferred AMP and one preferred nCPAP as a long term treatment. Patients cited improved intrasubject variability observed in between the wash-in and wash-out periods. This highlights comfort, lack of noise, and portability as reasons for this preference. Compliance was the importance of follow up polysomnography in all patients treated with oral appliances to assessed subjectively by patient questionnaire data (fig 4) . There was no difference in the assess the efficacy of the treatment objectively.
The proposed mechanism of action of AMP is reported percentage of the night or nights per week treatment was used between the AMP that it increases upper airway size by advancing the mandible and tongue. 5 However, in at least and nCPAP groups. Based on our pre-study outcome definitions, 11 of the 20 (55%) were one of our patients the AMP increased the vertical space between the upper and lower treatment successes, one (5%) was a compliance failure, and eight (40%) were treatment incisors causing a downward rotation of the mandible and a decrease in upper airway size failures in the AMP group. In the nCPAP group 14 (70%) were treatment successes, six (30%) associated with an increase in the severity of the OSA. were compliance failures, and there were no treatment failures.
Our study has certain limitations. The sample size was relatively small and not all There were no clinical, polysomnographic, or cephalometric variables predictive of a suc-patients completed the study. One patient dropped out and another three refused to cross cessful treatment outcome with either AMP or nCPAP. Cephalometry data are presented in over to nCPAP after using the AMP. One compliance failure with the AMP and one with fig 5 with and without AMP in the patient who had a large increase in AHI with AMP. AMP nCPAP did not have follow up home sleep monitoring. Some of these problems are incaused a decrease in upper airway size associated with posterior movement of the tongue herent in any clinical trial. Our crossover design has excellent power characteristics for detecting and inferior movement of the hyoid bone.
group.bmj.com on April 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from small treatment effects and any potentially con-(55% versus 48%) and fewer compliance failures (5% versus 24%) compared with a nonfounding carry-over or period effects. 13 We used home sleep monitoring to establish treatment adjustable mandibular repositioning appliance when identical outcome definitions are used.
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efficacy. This was necessary because of the expense associated with the large number of Larger randomised clinical trials are necessary to determine further the precise indications, follow up studies. We believe home sleep monitoring is appropriate for treatment follow up benefits, and risks of each oral appliance in the treatment of OSA. These studies should once the diagnosis of OSA has been established. All treatment comparisons were made based include objective assessment of daytime sleepiness and performance, covert compliance on data from the home sleep monitoring and no comparisons were made with the initial monitoring, and long-term follow up. diagnostic polysomnography. Two recent stud- 
